DMAC has 36-month beta value of 1.43. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DMAC is 24.01M, and currently, short sellers hold a 0.73% ratio of that float. The average trading volume of DMAC on November 21, 2024 was 52.46K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DMAC) stock’s latest price update
The stock of DiaMedica Therapeutics Inc (NASDAQ: DMAC) has increased by 4.48 when compared to last closing price of 4.02.Despite this, the company has seen a gain of 1.94% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-14 that DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls – President, Chief Executive Officer & Director Scott Kellen – Chief Financial Officer & Company Secretary Lorianne Masuoka – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Chase Knickerbocker – Craig-Hallum Matthew Caufield – H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2024 Conference Call.
DMAC’s Market Performance
DiaMedica Therapeutics Inc (DMAC) has seen a 1.94% rise in stock performance for the week, with a -4.11% decline in the past month and a 5.00% surge in the past quarter. The volatility ratio for the week is 5.21%, and the volatility levels for the past 30 days are at 4.54% for DMAC. The simple moving average for the past 20 days is -1.10% for DMAC’s stock, with a 24.34% simple moving average for the past 200 days.
Analysts’ Opinion of DMAC
Many brokerage firms have already submitted their reports for DMAC stocks, with H.C. Wainwright repeating the rating for DMAC by listing it as a “Buy.” The predicted price for DMAC in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on October 07, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see DMAC reach a price target of $8. The rating they have provided for DMAC stocks is “Buy” according to the report published on April 24th, 2024.
Oppenheimer gave a rating of “Outperform” to DMAC, setting the target price at $7 in the report published on June 22nd of the previous year.
DMAC Trading at -2.00% from the 50-Day Moving Average
After a stumble in the market that brought DMAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.15% of loss for the given period.
Volatility was left at 4.54%, however, over the last 30 days, the volatility rate increased by 5.21%, as shares sank -6.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.13% lower at present.
During the last 5 trading sessions, DMAC fell by -1.21%, which changed the moving average for the period of 200-days by +31.29% in comparison to the 20-day moving average, which settled at $4.24. In addition, DiaMedica Therapeutics Inc saw 47.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DMAC starting from Von Koch Thomas, who purchase 1,200,000 shares at the price of $2.50 back on Jun 28 ’24. After this action, Von Koch Thomas now owns 5,526,435 shares of DiaMedica Therapeutics Inc, valued at $3,000,000 using the latest closing price.
STAHLBERG JAN, the 10% Owner of DiaMedica Therapeutics Inc, purchase 1,200,000 shares at $2.50 during a trade that took place back on Jun 28 ’24, which means that STAHLBERG JAN is holding 5,221,608 shares at $3,000,000 based on the most recent closing price.
Stock Fundamentals for DMAC
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.78 for the gross margin
The net margin for DiaMedica Therapeutics Inc stands at -0.7. The total capital return value is set at -0.49. Equity return is now at value -41.90, with -39.23 for asset returns.
Currently, EBITDA for the company is -19.31 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 5.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.81.
Conclusion
To put it simply, DiaMedica Therapeutics Inc (DMAC) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
